Only the study of cervical tissue sample of the uterus or endometrial allows a definitive diagnosis.
1.The diagnosis of endometrial cancer
2.The diagnosis of cancers of the cervix
3.Learn more about uterine cancer
The diagnosis of endometrial cancer
When symptoms suggest a suspected cancer of the endometrial, the doctor requested tests for confirmation. The diagnosis requires a taking a piece of the uterine wall. It may be a simple biopsy of the endometrial, biopsy or curettage with or without hysteroscopy. Hysteroscopy is an examination of exploring the inner wall of the body and cervix using a tiny camera (endoscope). It can be done without anesthesia general. When curettage is required, the examination is usually performed in a hospital under anesthesia.
The uterus is dilated with a gas to allow the insertion of a small sampling instrument. Curettage only takes a few minutes. The recovery takes about a day. However, pain and light bleeding may continue for one week. The tissues are then observed under a microscope. This analysis determines whether the tissue is cancerous or not. Examinations of imaging (CT and MRI) can also be practiced in order to seek a possible spread of the disease to other organs. Continue reading “CANCERS OF THE UTERUS: DIAGNOSIS”
A recent study, combined hormone replacement therapy for menopause, continuous take, does not increase the risk of uterine cancer. Instead, it would seem protective.
1.The advantages of hormone replacement therapy
At the time of menopause, hormone replacement therapy based on estrogen is prescribed to combat the risks of estrogen deficiency (both short term on the symptoms of menopause such as hot flashes , on the long term aging the skin , arteries, etc..). Estrogens promote the proliferation of endometrial cells, it is recommended to associate with a progestin, which compensates this effect. Thus, the risk of uterine cancer is not increased with the treatment, called “combined” combining estrogen and progesterone. There are two types: continuous or discontinuous engagement (14 days per cycle).
A team of researchers studied the effects of continuous combined hormone therapy in postmenopausal women with a cancer of the endometrial (uterine lining) by compared to a control population. Women who received continuous treatment, compared to patients not following any treatment, have a risk of uterine cancer by 0.6. This risk is 0.4 compared to intermittent hormone therapy. Taking continuous hormone substitutive over several years does not increase the risk of endometrial cancer, rather it tends to decrease, showing that combined form (estrogen and progesterone) is continuous in the most advantageous. Continue reading “HORMONE REPLACEMENT THERAPY CONTINUOUSLY DECREASES THE RISK OF UTERINE CANCER”